|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.12 USD | -0.08% |
|
+3.36% | -15.19% |
| 24/06 | AlphaValue/Baader Europe Reduces EPS Estimates for Genmab on Merger Financing Costs | MT |
| 23/06 | Genmab: Financing weighs now, pipeline pays later |  |
Business description: Genmab A/S
- royalties (83.4%);
- income from sales of products (10.7%);
- other (5.9%): primarily income from partnership agreement.
Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Number of employees: 3,088
Sales by Activity: Genmab A/S
| Fiscal Period: December | 2021 (DKK) | 2022 (DKK) | 2023 (DKK) | 2024 (DKK) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology | 848.2Cr | 1.46TCr | 1.65TCr | 2.15TCr | 372Cr |
Geographical breakdown of sales: Genmab A/S
| Fiscal Period: December | 2021 (DKK) | 2022 (DKK) | 2023 (DKK) | 2024 (DKK) | 2025 (USD) |
|---|---|---|---|---|---|
Denmark | 848.2Cr | 1.46TCr | 1.61TCr | 1.98TCr | 332.6Cr |
Japan | - | - | 4.1Cr | 84Cr | 21Cr |
United States of America | - | - | 38Cr | 90Cr | 18Cr |
Netherlands | - | - | - | - | 10L |
Executive Committee: Genmab A/S
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
Tahamtan Ahmadi
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/02/2021 |
Andrew Carlsen
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: Genmab A/S
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 66 | 01/01/2017 |
Deirdre Connelly
CHM | Chairman | 65 | 26/03/2020 |
| Director/Board Member | 53 | 29/03/2019 | |
| Director/Board Member | 61 | 29/03/2022 | |
Martin Schultz
BRD | Director/Board Member | 51 | 01/01/2022 |
Michael Kavanagh
BRD | Director/Board Member | - | 12/03/2025 |
Holdings: Genmab A/S
| Name | Stocks | % | Valuation |
|---|---|---|---|
GENMAB A/S 4.44% | 27,66,533 | 4.44% | 736 M $ |
Company details: Genmab A/S
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.33% | +1.37% | +64.03% | +119.11% | 5.53TCr | |
| +0.82% | +15.05% | +74.28% | +86.70% | 5.19TCr | |
| +1.36% | +0.36% | -14.06% | -14.69% | 2.28TCr | |
| -1.04% | +7.91% | +1.61% | +419.24% | 2.26TCr | |
| -0.18% | +7.20% | +32.16% | -14.07% | 1.74TCr | |
| -3.35% | +8.96% | +132.20% | +290.18% | 1.4TCr | |
| +2.89% | +5.51% | +27.11% | +181.45% | 1.34TCr | |
| +1.31% | +0.53% | +28.62% | - | 1.23TCr | |
| -0.22% | +1.36% | +71.16% | +117.94% | 1.18TCr | |
| Average | +0.21% | +4.21% | +46.35% | +148.23% | 2.46TCr | |
| Weighted average by Cap. | +0.32% | +4.83% | +50.02% | +133.28% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- Company Genmab A/S
Select your edition
All financial news and data tailored to specific country editions
